46 Results
Sort By:
Published on July 8, 2024
A team of researchers at the RIKEN Center for Integrative Medical Sciences (IMS) and Kyoto University in Japan has discovered several types of rare helper T cells that are associated with immune disorders such as multiple sclerosis and rheumatoid arthritis. The research, led by Yasuhiro Murakawa, systems biologist at RIKEN-IFOM…
Published on July 18, 2022
Research led by the Centre for Precision Health at Edith Cowan University in Perth confirms a genetic link between Alzheimer’s disease and gastrointestinal tract disorders. The scientists who carried out the study say their results show a shared susceptibility overlap for the two types of conditions across several genes involved…
Published on October 25, 2021
Nearly 40% of patients suffering from inflammatory bowel disease (IBD) also suffer from psychiatric disorders such as depression and anxiety. While the gut-brain axis is believed to drive these symptoms, the mechanisms have been unclear. Now, a new study from scientists at Humanitas University in Italy, shows the presence of…
Published on July 30, 2021
Using genome sequencing, Yale researchers report they have uncovered the underlying genetic cause of a rare childhood disorder. The recently identified disease termed “Deficiency in ELF4, X-linked,” or DEX for short, mimics inflammatory bowel disease. The research team is hopeful their work may help identify the roots of a host…
Published on May 23, 2019
Precision Medicine company Progenity, a developer of both diagnostic and therapeutic platforms, announced results from three studies that represent potential breakthrough methods for diagnosing, treating, and monitoring digestive diseases through ingestible technologies. The studies, which encompass both human and preclinical models, showed that the company’s ingestible diagnostic capsule provided autonomous…
Published on October 17, 2024
Research led by the Aalborg University in Denmark shows that a specific genetic variant is able to predict individuals who are likely to develop more severe ulcerative colitis. The researchers hope their findings will help guide treatment for the gastrointestinal autoimmune condition, which can be very variable in presentation. The…
Published on June 2, 2015
Sift through metadata. Track contact activity. Identify suspicious patterns. This to-do list sounds as though it were devised by the National Security Agency. But it actually describes a research plan enacted by a group of genomic scientists in Japan and the United Kingdom. The scientists sifted through a catalogue of…
Published on October 8, 2024
The trillions of microbes in the human gut play crucial roles in the development and progression of a range of autoimmune diseases, from inflammatory bowel disease to kidney disease and beyond. [CHRISTOPH BURGSTEDT/SCIENCE PHOTO LIBRARY/Getty Images] As many as one in 10 people in the U.K.…
Published on October 8, 2024
Some of the earliest observations of human health have proposed a connection between what is happening in the human gut and mental health—the now well-known gut–brain axis. However, researchers only began to make significant headway in these studies roughly 30 years ago. Today, research on the influence of the gut…
Published on September 26, 2024
An international, placebo-controlled clinical study led by Cedars-Sinai researchers has found that a new drug therapy for moderate to severe ulcerative colitis is safe and effective in helping patients achieve clinical remission. The results of the Phase II trial are published in The New England Journal of Medicine. Ulcerative colitis,…
Published on March 27, 2024
Continuing a trend, yesterday AbbVie announced it will acquire Landos, a clinical-stage biotech focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action…
Published on December 4, 2023
AstraZeneca is the latest big pharma to partner with a company using artificial intelligence (AI) to help design drugs in a collaboration with U.S.-based Absci to design a cancer fighting antibody drug. According to the Financial Times, who announced the deal over the weekend, the partnership is worth up to…
Published on July 31, 2023
Direct injection of neonatal mesenchymal stem cells (MSCs) from discarded heart tissue from surgery could aid in healing Crohn’s disease, according to new research from investigators at the Ann & Robert H. Lurie Children’s Hospital of Chicago. The study, published in the journal Advanced Therapeutics, found that the technique, reduced…
Published on July 10, 2023
Thermo Fisher is acquiring CorEvitas, a provider of U.S. based regulatory-grade, real-world evidence for approved medical treatments and therapies, mainly for immune diseases, from Audax Private Equity for $912.5 million in cash. “The addition of CorEvitas will further advance our capabilities to better serve our pharma and biotech customers and…
Published on June 20, 2023
Eli Lilly today announced it is buying DICE Therapeutics for $2.4 billion. DICE applies its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including IL-17 inhibitors, to treat chronic autoimmune and inflammatory diseases, which are usually treatment with injectables. Its lead products are DC-806, in Phase II, and…